Skip to main content
Top
Published in: Internal and Emergency Medicine 8/2016

01-12-2016 | IM - ORIGINAL

Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry

Authors: Francesco Violi, Roberto Gino Corazza, Stephen Hugh Caldwell, Francesco Perticone, Angelo Gatta, Mario Angelico, Alessio Farcomeni, Michela Masotti, Laura Napoleone, Annarita Vestri, Valeria Raparelli, Stefania Basili, PRO-LIVER Collaborators

Published in: Internal and Emergency Medicine | Issue 8/2016

Login to get access

Abstract

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients. Viral (44 %) etiology was predominant. Around half of the patients had a mild-severity disease according to the Child–Pugh score; hepatocellular carcinoma was present in 20 %. The prevalence of ultrasound-detected portal vein thrombosis was 17 % (n = 126); it was asymptomatic in 43 % of the cases. Notably, more than half of the portal vein thrombosis patients (n = 81) were not treated with anticoagulant therapy. Logistic step-forward multivariate analysis demonstrated that previous portal vein thrombosis (p < 0.001), Child–Pugh Class B + C (p < 0.001), hepatocellular carcinoma (p = 0.01), previous upper gastrointestinal bleeding (p = 0.030) and older age (p = 0.012) were independently associated with portal vein thrombosis. Portal vein thrombosis is a frequent complication of cirrhosis, particularly in patients with moderate–severe liver failure. The apparent undertreatment of patients with portal vein thrombosis is a matter of concern and debate, which should be addressed by planning interventional trials especially with newer oral anticoagulants.
Clinicaltrials.gov identifier NCT01470547.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365:147–156CrossRefPubMed Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365:147–156CrossRefPubMed
2.
go back to reference Ferro D, Angelico F, Caldwell SH, Violi F (2012) Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis 44:275–279CrossRefPubMed Ferro D, Angelico F, Caldwell SH, Violi F (2012) Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis 44:275–279CrossRefPubMed
3.
go back to reference Fimognari FL, Violi F (2008) Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 3:213–218CrossRefPubMed Fimognari FL, Violi F (2008) Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 3:213–218CrossRefPubMed
4.
go back to reference Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK (2010) Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 31:366–374CrossRefPubMed Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK (2010) Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 31:366–374CrossRefPubMed
5.
go back to reference Yang ZJ, Costa KA, Novelli EM, Smith RE (2014) Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost 20:169–178CrossRefPubMed Yang ZJ, Costa KA, Novelli EM, Smith RE (2014) Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost 20:169–178CrossRefPubMed
6.
go back to reference Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH et al (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 101:1524–1528CrossRefPubMed Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH et al (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 101:1524–1528CrossRefPubMed
7.
go back to reference Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H et al (2011) The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 9:1CrossRefPubMedPubMedCentral Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H et al (2011) The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 9:1CrossRefPubMedPubMedCentral
8.
go back to reference Zocco MA, Di Stasio E, De Cristofaro R (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51:682–689CrossRefPubMed Zocco MA, Di Stasio E, De Cristofaro R (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51:682–689CrossRefPubMed
9.
go back to reference Alkim H, Ayaz S, Sasmaz N, Oguz P, Sahin B (2012) Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis. Clin Appl Thromb Hemost 18:409–415CrossRefPubMed Alkim H, Ayaz S, Sasmaz N, Oguz P, Sahin B (2012) Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis. Clin Appl Thromb Hemost 18:409–415CrossRefPubMed
10.
go back to reference Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L et al (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40:736–741CrossRefPubMed Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L et al (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40:736–741CrossRefPubMed
11.
go back to reference Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE et al (2015) Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61:660–667CrossRefPubMed Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE et al (2015) Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61:660–667CrossRefPubMed
12.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRefPubMed Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRefPubMed
13.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470CrossRefPubMed Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470CrossRefPubMed
14.
go back to reference D’Amico G, Garcia-Tsao G, Abraldes J, Ginès P, Kim WR, Schepis F, et al (2005) Prognostic indicators in cirrhosis. In: de Franchis R (ed) Portal Hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Blackwell, Oxford D’Amico G, Garcia-Tsao G, Abraldes J, Ginès P, Kim WR, Schepis F, et al (2005) Prognostic indicators in cirrhosis. In: de Franchis R (ed) Portal Hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Blackwell, Oxford
15.
go back to reference Yerdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J et al (2000) Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 69:1873–1881CrossRefPubMed Yerdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J et al (2000) Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 69:1873–1881CrossRefPubMed
16.
go back to reference Violi F, Ferro D, Basili S, Lionetti R, Rossi E, Merli M et al (1997) Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 77:44–47PubMed Violi F, Ferro D, Basili S, Lionetti R, Rossi E, Merli M et al (1997) Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 77:44–47PubMed
17.
go back to reference Basili S, Merli M, Ferro D, Lionetti R, Rossi E, Riggio O et al (1999) Clotting activation after transjugular intrahepatic portosystemic stent shunt. Thromb Haemost 81:711–714PubMed Basili S, Merli M, Ferro D, Lionetti R, Rossi E, Riggio O et al (1999) Clotting activation after transjugular intrahepatic portosystemic stent shunt. Thromb Haemost 81:711–714PubMed
18.
go back to reference Basili S, Raparelli V, Violi F (2010) The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med 21:62–64CrossRefPubMed Basili S, Raparelli V, Violi F (2010) The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med 21:62–64CrossRefPubMed
19.
go back to reference Nolan JP (2010) The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 52:1829–1835CrossRefPubMed Nolan JP (2010) The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 52:1829–1835CrossRefPubMed
20.
go back to reference Giannini EG, Stravitz RT, Caldwell SH (2015) Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see. Hepatology. doi:10.1002/hep.27875 Giannini EG, Stravitz RT, Caldwell SH (2015) Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see. Hepatology. doi:10.​1002/​hep.​27875
21.
go back to reference Violi F, Ferro D (2013) Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost 39:426–433CrossRefPubMed Violi F, Ferro D (2013) Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost 39:426–433CrossRefPubMed
22.
go back to reference Fimognari FL, De Santis A, Piccheri C, Moscatelli R, Gigliotti F, Vestri A et al (2005) Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 146:238–243CrossRefPubMed Fimognari FL, De Santis A, Piccheri C, Moscatelli R, Gigliotti F, Vestri A et al (2005) Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 146:238–243CrossRefPubMed
23.
go back to reference Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK (2011) Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol 55:1415–1427CrossRefPubMed Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK (2011) Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol 55:1415–1427CrossRefPubMed
24.
go back to reference Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143:1253–1260CrossRefPubMed Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143:1253–1260CrossRefPubMed
25.
go back to reference Lisman T, Kamphuisen PW, Northup PG, Porte RJ (2013) Established and new-generation antithrombotic drugs in patients with cirrhosis—possibilities and caveats. J Hepatol 59:358–366CrossRefPubMed Lisman T, Kamphuisen PW, Northup PG, Porte RJ (2013) Established and new-generation antithrombotic drugs in patients with cirrhosis—possibilities and caveats. J Hepatol 59:358–366CrossRefPubMed
26.
go back to reference Violi F (2015) Should the term coagulopathy in cirrhosis be abandoned? JAMA Intern Med 175:862–863CrossRefPubMed Violi F (2015) Should the term coagulopathy in cirrhosis be abandoned? JAMA Intern Med 175:862–863CrossRefPubMed
Metadata
Title
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry
Authors
Francesco Violi
Roberto Gino Corazza
Stephen Hugh Caldwell
Francesco Perticone
Angelo Gatta
Mario Angelico
Alessio Farcomeni
Michela Masotti
Laura Napoleone
Annarita Vestri
Valeria Raparelli
Stefania Basili
PRO-LIVER Collaborators
Publication date
01-12-2016
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 8/2016
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-016-1416-8

Other articles of this Issue 8/2016

Internal and Emergency Medicine 8/2016 Go to the issue

CE - MEDICAL ILLUSTRATION

Edematous face

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.